Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; and signal transduction), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions. Molecular Cancer Research accepts submissions of primary research, review and commentary article types as well as letters to the editor. For descriptions and length requirements of the article types available to submitting authors see the Categories of Articles for Molecular Cancer Research. The AACR Journals all use a similar Editorial Process. Please note that Molecular Cancer Research does not consider appeals. Submitting authors must be familiar with the Editorial Policies of the AACR Journals covering important information on authorship, publishing ethics, availability of materials and data and data analysis and reporting. Manuscripts are stringently reviewed for high standards of scientific merit, and only those that report results of novel, timely, and broadly-significant research are accepted for publication.
分子癌症研究发表文章描述了对该领域有广泛兴趣的新的基础癌症研究发现。研究必须具有证明意义,并且该杂志将分子和细胞水平的分析放在首位,揭示了与癌症风险、发展和/或进展相关的途径和过程的新的机械洞察。重点领域包括所有癌症相关途径(包括细胞周期调节、细胞死亡、染色质调节、DNA损伤和修复、基因和RNA调节、基因组学、癌基因和肿瘤抑制因子以及信号转导),以及描述支持癌症表型的新分子机制和相互作用的研究。为了充分考虑,提交的初步研究必须提供对现有通路功能的重要新见解,或解决与癌症相关的生物学问题相关的新假设。 分子癌症研究接受提交的初步研究,评论和评论文章类型以及给编辑的信件。有关提交给作者的文章类型的描述和长度要求,请参阅分子癌症研究的文章类别。AACR期刊都使用类似的编辑过程。请注意,分子癌症研究不考虑上诉。 提交作者必须熟悉AACR期刊的编辑政策,包括关于作者身份、出版道德、材料和数据的可用性以及数据分析和报告的重要信息。 对手稿进行严格的审查,以获得高标准的科学价值,只有那些报告小说、及时和广泛重要研究成果的手稿才被接受出版。
期刊ISSN
|
1541-7786 |
最新的影响因子
|
5.2 |
最新CiteScore值
|
4.65 |
最新自引率
|
2.10% |
期刊官方网址
|
http://mcr.aacrjournals.org/ |
期刊投稿网址
|
http://mcr.msubmit.net/cgi-bin/main.plex |
通讯地址
|
AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 |
偏重的研究方向(学科)
|
医学-细胞生物学 |
出版周期
|
Monthly |
平均审稿速度
|
偏慢,4-8周 |
出版年份
|
2002 |
出版国家/地区
|
UNITED STATES |
是否OA
|
No |
SCI期刊coverage
|
Science Citation Index Expanded(科学引文索引扩展) |
NCBI查询
|
PubMed Central (PMC)链接 全文检索(pubmed central) |
最新中科院JCR分区
|
大类(学科)
小类(学科)
JCR学科排名
医学
CELL BIOLOGY(细胞生物学) 2区
ONCOLOGY(肿瘤学) 2区
59/190
57/223
|
|||||||
最新的影响因子
|
5.2 | |||||||
最新公布的期刊年发文量 |
|
|||||||
总被引频次 | 7899 | |||||||
特征因子 | 0.013800 | |||||||
影响因子趋势图 |
2007年以来影响因子趋势图(整体平稳趋势)
|
最新CiteScore值
|
4.65
=
引文计数(2018)
文献(2015-2017)
=
1993次引用
429篇文献
|
||||||||||
文献总数(2014-2016) | 429 | ||||||||||
被引用比率
|
93% | ||||||||||
SJR
|
2.428 | ||||||||||
SNIP
|
1.096 | ||||||||||
CiteScore排名
|
|
||||||||||
CiteScore趋势图 |
CiteScore趋势图
|
||||||||||
scopus涵盖范围 |
scopus趋势图
|
本刊同领域相关期刊
|
|
期刊名称 | IF值 |
NEURO-ONCOLOGY | 15.9 |
JOURNAL OF NEURO-ONCOLOGY | 3.9 |
OncoImmunology | 7.2 |
JOURNAL OF IMMUNOTHERAPY | 3.9 |
Cancer Immunology Research | 10.1 |
Infectious Agents and Cancer | 3.7 |
CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.8 |
INTEGRATIVE CANCER THERAPIES | 2.9 |
Hormones & Cancer | 3 |
本刊同分区等级的相关期刊
|
|
期刊名称 | IF值 |
JOURNAL OF IMMUNOTHERAPY | 3.9 |
CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.8 |
Molecular Therapy-Oncolytics | 5.7 |
MOLECULAR CARCINOGENESIS | 4.6 |
MOLECULAR CANCER RESEARCH | 5.2 |
Journal of Geriatric Oncology | 3 |
GENES CHROMOSOMES & CANCER | 3.7 |
分享者 | 点评内容 |
发表日期:2014-12-25 |
研究方向:肿瘤
之前被接收一篇,最近尝试投了篇被拒稿了,要求还是很高的,文章质量一般的就不要试了。
(0)
|